

**HEALTHY
BIOSCIENCES
PRIVATE LIMITED**



**ANNUAL REPORT
2021-2022**

COMPANY INFORMATION

Name of the Company

HEALTHY BIOSCIENCES PRIVATE LIMITED

CIN

U24296PB2008PTC032037

Board of Directors

**Mr. Gursimran Singh
Mr. Charanjit Singh Bhatia
Mrs. Simmi Chhabra**

**Company Secretary
& Compliance Officer**

Mr. Jagkirat Singh (w.e.f 08.11.2021)

Statutory Auditor

**M/s Harjeet Parvesh & Co., Practicing Chartered
Accountant**

Registered Office

**Plot No. 986, Sector 82, Janta Industrial Estate, Mohali
160062**

Banker

**Union Bank of India
Mohali Main, SAS Branch, Ludhiana-160059**

NOTICE CONVENING 14th ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN THAT THE 14th ANNUAL GENERAL MEETING OF THE MEMBERS OF HEALTHY BIOSCIENCES PRIVATE LIMITED WILL BE HELD ON SATURDAY, 30th JULY, 2022, AT 09:30 A.M. AT THE REGISTERED OFFICE OF THE COMPANY SITUATED AT PLOT NO. 986, SECTOR 82, JANTA INDUSTRIAL ESTATE, MOHALI, PUNJAB, TO TRANSACT THE FOLLOWING BUSINESS:

ORDINARY BUSINESS:

1. To receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended March 31, 2022, together with the Reports of the Auditors and the Board of Directors thereon.
2. To ratify the appointment of M/s. Harjeet Parvesh & Co., Chartered Accountants and fix their remuneration.

To consider and if thought fit, to pass with or without modification(s), the following resolution as an **Ordinary Resolution**:

“RESOLVED that pursuant to the provisions of Section 139 and other applicable provisions, if any, of the Companies Act, 2013 and the Rules framed thereunder (including any statutory modification(s) or re-enactment thereof for the time being in force), the appointment of M/s. Harjeet Parvesh & Co., Chartered Accountants (Firm's Registration No. 017437N), as the Statutory Auditors of the Company, be and is hereby ratified to hold office from the conclusion of this Annual General Meeting till the conclusion of the next Annual General Meeting at such remuneration plus applicable service tax and reimbursement of out-of-pocket expenses as may be mutually agreed between the Board of Directors of the Company and the Statutory Auditors.”

By Order of the Board of Directors
Healthy Biosciences Private Limited

Place: Mohali
Date: 02.07.2022

Charanjit Singh Bhatia
Director
DIN - 01954419

Gursimran Singh
Director
DIN- 02209675

NOTES:

1. MEMBER ENTITLED TO ATTEND AND VOTE IN THE ABOVE MEETING IS ENTITLED TO APPOINT ONE OR MORE PROXIES TO ATTEND AND ON A POLL, TO VOTE INSTEAD OF HIMSELF AND PROXY NEED NOT BE A MEMBER.
2. The instrument appointing a proxy shall a) Be in writing and b) Be signed by the appointer or his attorney duly authorized in writing or if the appointer is a body corporate, be under its seal or be signed by an officer or an attorney duly authorized by it.
3. A person can act as proxy on behalf of the member not exceeding Fifty (50) and holding in aggregate not more than 10% of the total share capital carrying voting rights.
4. A member holding more than 10% of the total share capital carrying voting rights may appoint single person as proxy and such person shall not act as proxy for any other person or shareholder.
5. Corporate members to authorize representative to attend the meeting through resolution.
6. Proxies in order to be effective should be lodged with the Company at the Registered Office of the Company at least 48 hours before the commencement of the meeting.
7. Every member entitled to vote at the meeting of the company may inspect the proxies lodged at time during the business hours of the company provided not less than Three (3) days' notice in writing of the intention to do so is given to the company.
8. Members are requested to bring the attendance slips alongwith their copies of the Notice to the meeting.
9. Member who wishes to update or register their email addresses with the company may contact the Company at healthybiosciences118@gmail.com.

By Order of the Board of Directors
Healthy Biosciences Private Limited

Place: Mohali
Date: 02.07.2022

Charanjit Singh Bhatia
Director
DIN - 01954419

Gursimran Singh
Director
DIN- 02209675

HEALTHY BIOSCIENCES PRIVATE LIMITED

Regd. Office: PLOT NO. 986, SECTOR 82, JANTA INDUSTRIAL ESTATE, MOHALI, PUNJAB
CIN: U24296PB2008PTC032037

ATTENDANCE SLIP

(To be presented at the entrance)

Members Name	DP ID
Proxy Name	Folio No./Client ID

I/We hereby record my/our presence at the **14th ANNUAL GENERAL MEETING** of the Company held on Saturday, 30th July, 2022 at 09.30 a.m. at the registered office of the Company situated at Plot No. PLOT NO. 986, SECTOR 82, JANTA INDUSTRIAL ESTATE, MOHALI, PUNJAB.

PLEASE COMPLETE THIS ATTENDANCE SLIP AND HAND IT OVER AT THE ENTRANCE OF THE MEETING HALL. JOINT SHAREHOLDER(S) MAY OBTAIN ADDITIONAL SLIP AT THE VENUE OF THE MEETING.

Signature of the Member/Proxy

Form No. MGT-11

Proxy form

[Pursuant to Section 105(6) of the Companies Act, 2013 and Rule 19(3) of the Companies (Management and Administration) Rules, 2014]

CIN: U24296PB2008PTC032037

Name of the Company: HEALTHY BIOSCIENCES PRIVATE LIMITED

Registered office: PLOT NO. 986, SECTOR 82, JANTA INDUSTRIAL ESTATE, MOHALI PUNJAB 160062

Name of the Member(s):

Registered address:

E-mail Id:

Folio No/ Clint Id:

DP ID:

I/ We being the member of, holding.....shares, hereby appoint

1. Name:

Address:

E-mail Id:

Signature:, or failing him

2. Name:

Address:

E-mail Id:

Signature:,

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at 14th Annual General Meeting of members of the Company, to be held on Saturday 30th July 2022 at 09.30 a.m. registered office of the Company at PLOT NO. 986, SECTOR 82, JANTA INDUSTRIAL ESTATE, MOHALI PUNJAB 160062 and at any adjournment thereof in respect of such resolutions as are indicated below:

Resolution No.

1 Adoption of Financial Statements for the F.Y. 2021-22 together with the Reports of the Auditors and the Board of Directors thereon

2 Ratification of appointment of M/s. Harjeet Parvesh & Co.,
Chartered Accountants and fix their remuneration.

Affix
Revenue
Stamp

Signed this day of..... 2022

Signature of Shareholder

Signature of Proxy holder(s)

Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, before the commencement of the Meeting.

DIRECTORS' REPORT

Your Directors are pleased to present the 14th Annual Report covering the operational and financial performance of your Company along with the Audited Financial Statements for the financial year ended March 31, 2022.

1. FINANCIAL HIGHLIGHTS:

The Standalone Financial results are briefly indicated below:

<i>(Amount in Rs.)</i>		
Particulars	2021-22	2020-21
Revenue from Operations	51,94,091.00	53,16,958.00
Other Income	33,95,559.00	27,39,251.00
Profit/loss before Depreciation, Finance Costs, Exceptional items and Tax Expense	28,37,568.00	29,94,564.89
Less: Depreciation/ Amortization/ Impairment	0.00	0.00
Profit /loss before Finance Costs, Exceptional items and Tax Expense	28,37,568.00	29,94,564.89
Less: Finance Costs	17,83,564.00	25,35,504.15
Profit /loss before Exceptional items and Tax Expense	10,54,004.00	4,59,060.74
Add/(less): Exceptional items	0.00	0.00
Profit /loss before Tax Expense	10,54,004.00	4,59,060.74
Less: Tax Expense		
• Current Tax	0.00	0.00
• Deferred Tax	(9,64,562.00)	(11,29,051.00)
• MAT Credit Entitlement	0.00	0.00
Profit /loss for the year	89,442.00	(6,69,990.26)

2. REVIEW OF OPERATION:

During the financial year under review, the company has earned Rs. 85,89,649.00 income whereas last financial year's income of the company amounted to Rs. 80,56,209/-. The company incurred expenditure (including depreciation) of Rs. 75,35,645/- in the current financial year as compared to expenditure (including depreciation) of Rs. 75, 97,148.26/- in the previous financial year under review. The Company managed to earn a profit of Rs. 89,442.00 /- the current financial year under review as compared to the loss of Rs. 6,69,990/- in the previous financial year. Your management is striving hard to further improve the financial position of the Company by devising effective marketing plans and strategies.

3. CHANGE IN THE NATURE OF BUSINESS, IF ANY

There were no changes in the nature of business during the financial year ended 31st March 2022.

4. DIVIDEND

Your Directors have not recommended any dividend for the Financial Year ended 31st March 2022.

5. RESERVES

The profit of Rs. 89,442/- for the year ending 31st March, 2022 amounting to Rs. has been transferred to the Reserves & Surplus.

6. CHANGE OF NAME

There is no change in the name of the company during the year under review.

7. SHARE CAPITAL

The Authorized Share Capital of the company remains at Rs. 10,00,00,000/- divided into 1,00,00,000 Equity Shares of Rs. 10/- each. The issued, subscribed and paid up share capital is Rs. 10,00,00,000/- divided into 1,00,00,000 Equity Shares of Rs. 10 /- each.

8. MATERIAL CHANGES AND COMMITMENTS AFFECTING FINANCIAL POSITION BETWEEN END OF THE FINANCIAL YEAR AND THE DATE OF THIS REPORT

There have been no material changes and commitments affecting the financial position of the Company which have occurred between the end of the financial year of the Company to which the financial statements relate and the date of the report.

9. DEPOSITS

During the period under review the Company has neither accepted nor invited any Public deposits. Hence the provisions of Section 76 of the Companies Act, 2013 read with the Companies (Acceptance of Deposits) Rules, 2014 are not applicable.

10. RELATED PARTY TRANSACTIONS

During the financial year ended March 31, 2021, all transactions with the Related Parties as defined under the Companies Act, 2013 read with Rules framed thereunder were in the 'ordinary course of business' and 'at arm's length' basis.

Form AOC-2 containing particulars of contracts or arrangements entered into by the Company with related parties referred in Section 188(1) of the Companies Act, 2013 is attached as '**Annexure - A**'. Details of related party transactions and related disclosures are given in the notes to the financial statements.

11. DETAILS OF SUBSIDIARY/JOINT VENTURES/ASSOCIATE/HOLDING COMPANIES:

The Company had no subsidiary, Joint ventures, Associate or Holding Companies as per the provisions of Companies Act, 2013 as on 31st March, 2022.

12. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUT GO

Information in accordance with the provisions of Section 134 (3)(m) of the Act read with the Companies (Disclosure of Particulars in the Report of Board of Directors) Rules, 1988, regarding Conservation of Energy, Technology Absorption and Foreign Exchange Earnings and Outgo is not applicable on the Company.

13. DIRECTORS AND KEY MANAGERIAL PERSONNEL:

During the year under review, Mr. Jagkirat Singh, an Associate Member of the Institute of Company Secretaries of India (Membership No.ACS- 67217) was appointed as a Company Secretary with effect from 08th November, 2021. Mr. Jagkirat Singh placed his resignation to the Board of Directors which was accepted with effect from 31/05/2022. Further, there was no change in the directorship and key managerial personnel of the company.

14. PARTICULARS OF EMPLOYEES

Disclosure required under Section 197 of the Companies Act, 2013 read with rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 as amended up to date is not applicable since your Company has no such employees.

15. BOARD MEETINGS

The Board has met 9 (Nine) times during the financial year, the details of which are as under:

25.04.2021, 17.05.2021, 28.06.2021, 27.08.2021, 20.09.2021, 08.10.2021, 08.11.2021, 02.02.2022 and 10.02.2022.

Details of Attendance of Directors:

S.No.	Name of the Director	Number of Meetings entitled to attend	Number of Meetings attended
1.	Mr. Charanjit Singh Bhatia	9	9
2.	Mr. Gursimran Singh	9	9
3.	Ms. Simmi Chhabra	9	9

Details of number of meeting attended by Directors:

S.No.	Date of Meeting	Number of Directors entitled to attend	Number of Directors attended
1.	25.04.2021	3	3
2.	17.05.2021	3	3
3.	28.06.2021	3	3
4.	27.08.2021	3	3
5.	20.09.2021	3	3
6.	08.10.2021	3	3
7.	08.11.2021	3	3
8.	02.02.2022	3	3
9.	10.02.2022	3	3

16. DECLARATION BY AN INDEPENDENT DIRECTOR(S) AND RE- APPOINTMENT, IF ANY

The provisions of Section 149 for appointment of Independent Directors do not apply to the company.

17. NOMINATION & REMUNERATION COMMITTEE POLICY AND MANAGERIAL REMUNERATION

The provisions of Section 178(1) relating to constitution of Nomination and Remuneration Committee are not applicable to the Company and hence the company has not devised any policy relating to appointment of directors, payment of managerial remuneration, directors qualification, positive attributes, independence of directors and other related matters as provided under Section 178(3) of the Companies Act, 2013.

18. AUDITORS & AUDITORS REPORT:

In terms of the provisions of Section 139 of the Companies Act, 2013 read with provisions of the Companies (Audit and Auditors) Rules, 2014 as amended, M/s. Harjeet Parvesh & Co., Chartered Accountants (Firm Registration No. 017437N) were appointed as the Auditors of the Company for a consecutive period of 5 (five) years from conclusion of the 10th AGM held in the year 2017 until conclusion of the 15th AGM of the Company scheduled to be held in the year 2023. Your directors propose to ratify their appointment for the Financial Year 2022-23.

Your Company has received a confirmation that they hold a valid certificate issued by the Peer Review Board of the ICAI as required under the provisions of Regulation 33 of the Listing Regulations.

19. CORPORATE SOCIAL RESPONSIBILITY (CSR) POLICY

The provisions of Section 135 of the Companies Act, 2013 regarding Corporate Social Responsibility are not applicable to the company.

20. ADOPTION OF INDIAN ACCOUNTING STANDARD (IND AS)

The Ministry of Corporate Affairs vide notification dated 16 February 2015 made it mandatory in a phased manner for adoption and applicability of Indian Accounting Standards (Ind AS) for companies other than Banking, Insurance and Non-Banking Finance Companies. Rule 4 of the Companies (Indian Accounting Standards) Rules 2015 specifies the classes of companies which shall comply with the Ind AS in preparation of the financial statements. In accordance with clause (iii) of sub rule (1) of the Rule 4 of the Companies (Indian Accounting Standards) Rules 2015, the compliance of Indian Accounting Standards was applicable and mandatory to the company for the accounting

period beginning from 1 April 2017. The financial statements for the year under review have been prepared in accordance with the Ind AS.

21. DETAILS IN RESPECT OF FRAUDS REPORTED BY AUDITORS

There was no fraud reported by the Auditors as prescribed under Sub Section (12) of Section 143 of the Companies Act, 2013 during the Financial Year under review.

22. SECRETARIAL AUDIT REPORT

The provisions of Secretarial Audit Report is not applicable to our Company.

23. COMPLIANCE WITH SECRETARIAL STANDARDS

During the year under review, the Company has duly complied with the applicable provisions of the Secretarial Standards on Meetings of the Board of Directors (SS-1) and General Meetings (SS-2) issued by The Institute of Company Secretaries of India(ICSI).

24. DISCLOSURE OF COMPOSITION OF AUDIT COMMITTEE AND PROVIDING VIGIL MECHANISM

The provisions of Section 177 of the Companies Act, 2013 read with Rule 6 and 7 of the Companies (Meetings of the Board and its Powers) Rules, 2013 is not applicable to the Company.

25. MAINTENANCE OF COST RECORDS

The provisions of maintenance of cost audit records under sub-section (1) of section 148 of the Companies Act, 2013 and getting the same audited are not applicable to the Company.

26. ADEQUACY OF INTERNAL FINANCIAL CONTROLS

Your Company has an adequate system of internal financial controls commensurate with its size and scale of operations, procedures and policies, ensuring orderly and efficient conduct of its business, including adherence to the Company's policies, safeguarding of its assets, prevention and detection of frauds and errors, accuracy and completeness of accounting records, and timely preparation of reliable financial information.

27. RISK MANAGEMENT POLICY

The Company has adopted a Risk Management Policy to ensure coverage against internal and external threats to the business of the Company. The Management has perceived the business of the Company in such a manner which ensures proper risk management.

28. EXTRACT OF ANNUAL RETURN

The extracts of Annual Return in form MGT-9 pursuant to the provisions of Section 92 read with Rule 12 of the Companies (Management and administration) Rules, 2014 is furnished in **Annexure “B”** and is attached to this Report.

29. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS UNDER SECTION 186

During the year under review, company has not granted any loan and has not made any investments under Section 186 of the Companies Act 2013. Further, particulars of guarantees made during the year is as below.

Details of Guarantee / Security Provided:

SL No	Date of providing security / guarantee	Details of recipient	Amount (Rs.)	Purpose for which the security/ guarantee is proposed to be utilized by the recipient	Date of BR	Date of SR (if any)	Commission
1	28.03.22	Ajooni Biotech Limited	1013.89 Lakhs	Working Capital and Term Loan	17.05.21	-	-

30. DISCLOSURES UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

In order to prevent sexual harassment of women at work place a new act The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 has been notified on 9th December, 2013. Under the said Act every company is required to set up an Internal Complaints Committee to look into complaints relating to sexual harassment at work place of any women employee.

Your Company has adopted a policy for prevention of Sexual Harassment of Women at workplace and has set up Committee for implementation of said policy. During the year Company has not received any complaint of harassment.

31. TRANSFER OF AMOUNTS TO INVESTOR EDUCATION AND PROTECTION FUND

The Company was not required to transfer any amount to Investor Education and Protection Fund during the financial year ended on 31.03.2022.

32. DIRECTORS' RESPONSIBILITY STATEMENT

The Directors' Responsibility Statement referred to in clause (c) of sub-section (3) of Section 134 of the Companies Act, 2013, shall state that—

(a) in the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;

(b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and

fair view of the state of affairs of the company at the end of the financial year 2021-22 and of the profit and loss of the company for that period;

(c) The directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

(d) The directors had prepared the annual accounts on a going concern basis; and

(e) The directors, in the case of a listed company, had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.

(f) The directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

33. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS

There were no significant and material orders passed by the Regulators, Courts or Tribunals, during the year under review, which would impact the going concern status of the Company and its operations in future.

34. DISCLOSURE IN RESPECT OF VOTING RIGHTS NOT EXERCISED DIRECTLY BY THE EMPLOYEES IN RESPECT OF SHARES TO WHICH SCHEME FOR PROVISION OF MONEY FOR PURCHASE OF OR SUBSCRIPTION FOR SHARES BY EMPLOYEES OR BY TRUSTEES FOR THE BENEFIT OF EMPLOYEES

The disclosure under the provisions of Section 67(3) read with Rule 16(4) of the Companies (Share Capital and Debentures) Rules, 2014 in respect of voting rights not exercised directly by the employees in respect of shares to which scheme for provision of money for purchase of or subscription for shares by employees or by trustees for the benefit of employees is not applicable to the company.

35. PROCEEDINGS UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016

There are no proceedings initiated/ pending against your company under the Insolvency and Bankruptcy Code, 2016.

36. ONE-TIME SETTLEMENT AND VALUATION DONE WHILE TAKING LOAN FROM BANKS AND FINANCIAL INSTITUTIONS

Your Company has not taken loan from any Banks or Financial Institutions, and therefore, there was no one-time settlement as such.

37. TRADE RELATIONS

The Board wishes to place on record its appreciation for the support and co-operation that the Company received from its suppliers, distributors, retailers and other associates. The Company has always looked upon them as partners in its progress and has happily shared with them rewards of growth. It will be Company's endeavor to build and nurture strong links based on mutuality, respect and co-operation with each other and consistent with customer interest.

38. ACKNOWLEDGEMENTS

Your Directors place on record their sincere thanks to bankers, business associates, consultants, and various Government Authorities for their continued support extended to your Companies activities during the year under review. Your Directors also acknowledges gratefully the shareholders for their support and confidence reposed on your Company.

By Order of the Board of Directors
Healthy Biosciences Private Limited

Place: Mohali
Date: 02.07.2022

Charanjit Singh Bhatia
Director
DIN - 01954419

Gursimran Singh
Director
DIN- 02209675

ANNEXURE 'A' TO DIRECTORS' REPORT

FORM NO. AOC -2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014).

Form for Disclosure of particulars of contracts/arrangements entered into by the Company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arms length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at Arm's length basis.

SL. No.	Particulars	Details
1	Name (s) of the related party & nature of relationship	There are no such contracts or arrangements or transactions which are not at arm's length basis.
2	Nature of contracts/arrangements/transaction	
3	Duration of the contracts/arrangements/transaction	
4	Salient terms of the contracts or arrangements or transaction including the value, if any	
5	Justification for entering into such contracts or arrangements or transactions'	
6	Date of approval by the Board	
7	Amount paid as advances, if any	
8	Date on which the special resolution was passed in General meeting as required under first proviso to section 188	

2. Details of contracts or arrangements or transactions at Arm's length basis.

S.N o.	Name of the related party and nature of relationship	Nature of contracts/ arrangements/ transactions	Duration of the contracts/ arrangements / transactions	Salient terms of the Contracts or arrangements or transactions including the value, if any	Date(s) of Approval by the board	Amount paid as Advances, if any.
1.	Ajooni Biotech Limited	1.Purchases 2. Rent received	Transactions in normal course of business.	Purchases: Rs. 42,00,000/- Rent received- Rs. 2,12,400/-	25.04.21	N.A.
2.	Prism Medico and Pharmacy Limited	1. Repayments made against purchases 2. Rent Received	Transactions in normal course of business.	Repayments against purchases: Rs. 35,99,000/- Rent received- Rs. 70,800/-	25.04.21	N.A.

By Order of the Board of Directors
Healthy Biosciences Private Limited

Place: Mohali
Date: 02.07.2022

Charanjit Singh Bhatia
Director
DIN - 01954419

Gursimran Singh
Director
DIN- 02209675

ANNEXURE 'B' TO DIRECTORS' REPORT

FORM NO. MGT 9 EXTRACT OF ANNUAL RETURN

As on financial year ended on 31.03.2022

Pursuant to Section 92 (3) of the Companies Act, 2013 and rule 12(1) of the Company (Management & Administration) Rules, 2014.

I. REGISTRATION & OTHER DETAILS:

1.	CIN	U24296PB2008PTC032037
2.	Registration Date	26/06/2008
3.	Name of the Company	Healthy Biosciences Private Limited
4.	Category/Sub-category of the Company	Private Company Limited by shares/Indian Non - Government Company.
5.	Address of the Registered office & contact details	Plot No. 986, Sector 82, Janta Industrial Estate, Mohali - 160062
6.	Whether listed company	NO
7.	Name, Address & contact details of the Registrar & Transfer Agent, if any.	N.A.

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY (All the business activities contributing 10 % or more of the total turnover of the company shall be stated)

S. No.	Name and Description of main products / services	NIC Code of the Product/service	% to total turnover of the company
1	Retail trading of cattle feed	74999	100.00%

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES- NIL

Sl. no.	NAME AND ADDRESS OF THE COMPANY	CIN / GLN	HOLDIN G/SUBSI DIARY/ ASSOCI	% OF SHARES HELD	With Effect From	APPL ICAB LE SECT ION
	N.A.					

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

(i) Category-wise Share Holding

[illegible]

rand Total (A+B+C)		10000000	10000000	100		10000000	10000000	100	0
-------------------------------	--	----------	----------	-----	--	----------	----------	-----	---

(ii) Shareholding of Promoter-

SN	Shareholder's Name	Shareholding at the beginning of the year			Shareholding at the end of the year			% change in shareholding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	
1.	Prism Medico and Pharmacy Limited	1938000	19.38	-	0	0	-	-19.38
2.	Paramjit Kaur	1080000	10.80	-	1080000	10.80		-
3.	Ishneet Kaur	1560000	15.60	-	1560000	15.60		-
4.	Jasjot Singh	1800000	18	-	1900000	19		+1.00
5.	Punjab Biotechnology Park Limited	1700000	17	-	1938000	19.38		+2.38
6.	Sehejbir Singh Bhatia	1922000	19.22	-	1922000	19.22		-
7.	Gursimran Singh	0	0	-	1520000	15.20		+15.20
8.	Upneet Kaur	0	0	-	80000	0.80		+0.80

(iii) Change in Promoters' Shareholding :

S.No	Name of the Shareholder	Shareholding at the beginning of the year		Date	Reason	Increase/Decrease in Shareholding		Cumulative shareholding during the year	
		No. of Shares	% of total Shares of the company			No. of Shares	% of total Shares of the company	No. of Shares	% of total Shares of the company
1	Prism Medico and Pharmacy Limited	1938000	19.38	10.02.2022	Transfer of shareholding	Decrease in 1938000	(19.38)	0	0
2	Jasjot Singh	1800000	18.00	10.02.2022	Transfer of	Increase in	+1.00	1900000	19.00

					shareholding	100000			
3	Gursimran Singh	0	0	10.02.2022	Transfer of shareholding	Increase in 1520000	+15.20	1520000	15.20
4	Upneet Kaur	0	0	10.02.2022	Transfer of shareholding	Increase in 80000	+0.80	80000	0.80

**(iv) Shareholding Pattern of top ten Shareholders:
(Other than Directors, Promoters and Holders of GDRs and ADRs): NIL**

SN	For Each of the Top 10 Shareholders	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
01	At the beginning of the year	-	-	-	-
	Date wise Increase / Decrease in Promoters Shareholding during the year specifying the reasons for increase /decrease (e.g. allotment / transfer / bonus/ sweat equity etc.):	-			
	At the end of the year	-	-	-	-

(v) Shareholding of Directors and Key Managerial Personnel:

Sr . No	Director's, KMP / Shareholder's Name	Shareholding at the beginning of the year			Shareholding at the end of the year			
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total share	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	
1.	Charanjit Singh Bhatia	0	0	0	0	0	0	0

2.	Gursimran Singh	0	0	0	1520000	15.20	0	+15.20
3.	Simmi Chhabra	0	0	0	0	0	0	0
4.	Jagkirat Singh (CS)	0	0	0	0	0	0	0

V. INDEBTEDNESS -Indebtedness of the Company including interest outstanding/accrued but not due for payment.

Particulars	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	21976171.07	3780656.00	-	25756827.07
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
Total (i+ii+iii)	21976171.07	3780656.00	-	25756827.07
Change in Indebtedness during the financial year				
* Addition	-	-	-	-
* Reduction	(19299892.07)	(3780656.00)	-	
Net Change	(19299892.07)	(3780656.00)	-	(23080548.07)
Indebtedness at the end of the financial year				
i) Principal Amount	2676279.00	0.00	-	2676279.00
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
Total (i+ii+iii)	2676279.00	0.00	-	2676279.00

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL-

A. Remuneration to Managing Director, Whole-time Directors and/or Manager

SN.	Particulars of Remuneration	Name of MD , Whole-time Directors		Total Amount (Rs.)
		CHARANJIT SINGH BHATIA (DIRECTOR)	SIMMI CHHABRA (DIRECTOR)	
1	Gross salary	4,80,000	2,50,000	7,30,000
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	-	-	-
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	-	-	-
	(c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961	-	-	-

2	Stock Option	-	-	-
3	Sweat Equity	-	-	-
4	Commission - as % of profit - others, specify...	-	-	-
5	Others, please specify	-	-	-
	Total (A)	4,00,000	2,00,000	6,00,000
	Ceiling as per the Act	-	-	-

B. Remuneration to other directors: NIL

SN.	Particulars of Remuneration	Name of Directors		Total Amount in Rs.
1	Independent Directors	-	-	-
	Fee for attending board committee meetings	-	-	-
	Commission	-	-	-
	Others	-	-	-
	Total (1)	-	-	-
2	Other Executive Directors	-	-	-
	Fee for attending board committee meetings	-	-	-
	Commission	-	-	-
	Others, , REMUNERATION	-	-	-
	Total (2)	-	-	-
	Total (B)=(1+2)	-	-	-
	Total Managerial Remuneration	-	-	-
	Overall Ceiling as per the Act	-	-	-

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD:

SN	Particulars of Remuneration	Key Managerial Personnel			
		Plant Head	Jagkirat Singh (CS) w.e.f. 08/11/2022	CFO	Total
1	Gross salary	-	1,18,763	-	1,18,763
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	-	-	-	-
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	-	-	-	-
	(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	-	-	-	-
2	Stock Option	-	-	-	-
3	Sweat Equity	-	-	-	-
4	Commission	-	-	-	-
	- as % of profit	-	-	-	-

	others, specify...	-	-	-	-
5	Others, please specify	-	-	-	-
	Total	-	1,18,763	-	1,18,763

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

* There were no penalty, punishment, compounding of offences for the Company, directors or any other officers in default in respect of the Companies Act, 1956 & Companies Act, 2013.

By Order of the Board of Directors
Healthy Biosciences Private Limited

Place: Mohali
Date: 02.07.2022

Charanjit Singh Bhatia
Director
DIN - 01954419

Gursimran Singh
Director
DIN- 02209675

Independent Auditor's Report

To

The Members of M/s HEALTHY BIOSCIENCES PRIVATE LIMITED

Opinion

We have audited the accompanying standalone financial statements of **M/s HEALTHY BIOSCIENCES PRIVATE LIMITED** which comprise the Balance Sheet as at March 31, 2022, the Statement of Profit and Loss(statement of changes in equity),Cash Flow Statement for the year then ended,notes to the financial statements and a summary of significant accounting policies and other explanatory information.These financial statements are the responsibility of the company's management. Our responsibility is to express an opinion on these financial statements based on our audit.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid (Standalone) financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2022, and its Profit,(changes in equity) for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act.We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key Audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our

audit of the financial statements as a whole, and in forming our opinion thereon, and our opinion on these matters is as follows:

Depreciation Amounting Rs 27,12,565.23 is not charged during the year in the books of accounts as according to management there is no business carried on by the company during the year except for trading activities and assets have not been put to use.

Hence the book profit of M/s Healthy Biosciences Private Limited is increased by Rs 29,56,845.46 i.e. amount of depreciation not charged during year.

Management's Responsibility for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, (changes in equity) and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the audit of the Standalone Financial Statements

Our responsibility is to express an opinion on these (Standalone) financial statements based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act,

2013, we give in the **Annexure-A**, a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

2. As required by section 143 (3) of the Act, we report that:
- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
 - b) In our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
 - c) The Balance Sheet, the Statement of Profit and Loss dealt with by this Report are in agreement with the books of account
 - d) In our opinion, the aforesaid (Standalone) financial statements comply with the Accounting Standards specified under section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - e) On the basis of written representations received from the directors as on March 31, 2022 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2022 from being appointed as a director in terms of Section 164 (2) of the Act.
 - f) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For Harjeet Parvesh & Co.
Chartered Accountants
FRN: 017437N

CA Konica Madan (PARTNER)
M.No 547759
UDIN:22547759AMCXMG2835

Date: 02/07/2022
Place: MOHALI

Annexure A” to the Independent Auditors’ Report

Referred to in paragraph 1 under the heading ‘Report on Other Legal & Regulatory Requirement’ of our report of even date to the financial statements of the Company for the year ended March 31, 2022:

1) (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets;

(b) The Fixed Assets have been physically verified by the management in a phased manner, designed to cover all the items over a period of three years, which in our opinion, is reasonable having regard to the size of the company and nature of its business. Pursuant to the program, a portion of the fixed asset has been physically verified by the management during the year and no material discrepancies between the books records and the physical fixed assets have been noticed.

(c) The title deeds of immovable properties are held in the name of the company.

(d) The company has not revalued its Property, Plant and Equipment during the year.

(e) No proceedings have been initiated against the company for holding any Benami Property under the Benami Transactions (Prohibition) Act 1988 and rules made there under.

2) (a) The Management has conducted Physical verification of inventory at reasonable intervals and according to our opinion is reasonable having regard to the size of the company and nature of its business. There were No Discrepancies noticed on physical verification of the inventory.

(b) The quarterly returns or statements filed by company with banks or financial institutions are in agreement with the books of accounts.

3) a) The Company has not granted any loans or provided any advances in nature of Loans , secured or unsecured to Companies , firms , Limited Liability Partnerships or any other party.

However the company had opening balances of advances provided to following parties:

M/s Diamond Global Links : Rs 89,12,831/-

Mr Jayesh Mehta : Rs 27,50,000/-

Mr Kaushik Waghela : Rs 25,86,700/-

4) In our opinion and according to the information and explanations given to us, the company has complied with the provisions of section 185 and 186 of the Companies Act, 2013 In respect of loans, investments, guarantees, and security.

5) The Company has not accepted deposits from the public and hence the directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Act and the

Companies (Acceptance of Deposit) Rules, 2015 with regard to the deposits accepted from the public are not applicable.

6) As informed to us, the maintenance of Cost Records has not been specified by the Central Government under sub-section (1) of Section 148 of the Act, in respect of the activities carried on by the company.

7) (a) According to information and explanations given to us and on the basis of our examination of the books of account, and records, the Company has been generally regular in depositing undisputed statutory dues including Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs, Duty of Excise, Goods and Service Tax, Cess and any other statutory dues with the appropriate authorities. According to the information and explanations given to us, no undisputed amounts payable in respect of the above were in arrears as at March 31, 2022 for a period of more than six months from the date on when they become payable.

b) According to the information and explanation given to us, there are no dues of income tax, GST, duty of customs, duty of excise, value added tax outstanding on account of any dispute.

8) According to the information and explanation given to us, there are no transactions which have been surrendered or disclosed as income during the year in tax assessment under Income tax Act, 1961.

9) In our opinion and according to the information and explanations given to us, the Company has not defaulted in the repayment of dues to banks. The Company has not taken any loan either from financial institutions or from the government and has not issued any debentures.

- a) The company has not been declared a wilful defaulter by any bank or financial institution or any other lender.
- b) The term loans been used for the object for which they were obtained.
- c) The Company has not used funds raised for a short term basis for long term purposes.
- d) The company has not raised any money from any person or entity for the account of or to pay the obligations of its associates, subsidiaries or joint ventures.
- e) The company has not raised any loans during the year by pledging securities held in their subsidiaries, joint ventures or associate companies.

10) Based upon the audit procedures performed and the information and explanations given by the management, the company has not raised any moneys by way of initial public offer or further public offer including debt instruments and term loans. Accordingly, the provisions of clause (x) of the Order are not applicable to the Company and hence not commented upon.

11) Based upon the audit procedures performed and the information and explanations given by the management, we report that no fraud by the Company or on the company by its officers or employees has been noticed or reported during the year.

12) In our opinion, the Company is not a Nidhi Company. Therefore, the provisions of clause (xii) of the Order are not applicable to the Company.

13) In our opinion, all transactions with the related parties are in compliance with section 177 and 188 of Companies Act, 2013 and the details have been disclosed in the Financial Statements as required by the applicable accounting standards.

14) In our opinion, the provisions of section 138, of Companies Act 2013 are not applicable to the company , hence it is not required to have an internal auditor appointed Accordingly, the provisions of clause (xiv) of the Order are not applicable to the Company and hence not commented upon.

15) Based upon the audit procedures performed and the information and explanations given by the management, the company has not entered into any non-cash transactions with directors or persons connected with him. Accordingly, the provisions of clause (xv) of the Order are not applicable to the Company and hence not commented upon.

16) In our opinion, the company is not required to be registered under section 45 IA of the Reserve Bank of India Act, 1934 and accordingly, the provisions of clause (xvi) of the Order are not applicable to the Company and hence not commented upon.

17) In our opinion, the company has not incurred any cash losses in the financial year and in any preceding financial year.

18) There is no resignation of the statutory auditor during the year, accordingly, the provisions of clause (Xviii) of the Order are not applicable to the Company and hence not commented upon.

19) In our opinion, on the basis of financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of Board of directors and management's plans no material uncertainty exists as on date of audit report that company is not capable of meeting its liabilities at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.

20) In our opinion, the Provisions of Section 135(5) Of the Companies Act are not applicable to the company, the provisions of clause (xx) of the Order are not applicable to the Company and hence not commented upon.

21) In our opinion the financial statements are stand alone statement and consolidation is not required, the provisions of clause (xxi) of the Order are not applicable to the Company and hence not commented upon.

For Harjeet Parvesh & Co.
Chartered Accountants
FRN: 017437N

Date: 02/07/2022
Place: MOHALI

CA Konica Madan (PARTNER)
M.No 547759
UDIN:22547759AMCXMG2835

Annexure B” to the Independent Auditor’s Report of even date on the Financial Statements of M/sHEALTHY BIOSCIENCES PRIVATE LIMITED

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of M/sHEALTHY BIOSCIENCES PRIVATE LIMITED(“the Company”) as of March 31, 2022 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial controls These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial

statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2022.

**For Harjeet Parvesh & Co.
Chartered Accountants
FRN: 017437N**

**Date: 02/07/2022
Place: MOHALI**

**CA Konica Madan (PARTNER)
M.No 547759
UDIN:22547759AMCXMG2835**

HEALTHY BIOSCIENCES PRIVATE LIMITED**BALANCE SHEET
AS AT 31ST MARCH, 2022**

PARTICULARS	NOTES	31ST MARCH 2022	31ST MARCH 2021
<u>I. ASSETS</u>			
(1) <u>Non - Current Assets</u>			
(a) Property, Plant and Equipment	1	8,91,05,278	8,91,05,278
(b) Financial Assets			
(1) Non-Current Investments	2	3,13,05,775	1,60,52,823
(c) Other Non Current Assets	3	2,41,024	2,33,415
(2) <u>Current Assets</u>			
(a) Inventories	4	62,83,468	63,33,898
b) Financial Assets			
(1) Cash & Cash Equivalent	5	14,79,142	16,85,725
(2) Short Term Loans and advances	6	1,51,68,087	4,47,47,625
(3) Trade Receivables	7	17,60,000	
(c) Other Current Asset	8	16,27,497	14,33,054
	TOTAL Rs.	14,69,70,272	15,95,91,819
<u>II EQUITY AND LIABILITIES</u>			
(1) <u>Equity</u>			
(a) Equity Share Capital	9	10,00,00,000	10,00,00,000
(b) Other Equity	10	95,29,509	-53,35,805
(2) <u>Non- Current Liabilities</u>			
a) Financial Liabilities			
(1) Borrowings	11		37,80,656
(b) Deferred Tax Liabilty	24	26,77,290	17,12,728
(3) <u>Current Liabilities</u>			
(a) Financial Liabilities			
(1) Borrowings	12	26,76,279	2,19,76,171
(2) Trade Payables	13	2,73,02,523	2,66,42,423
(b) Other Current Liabilities	14	46,82,671	1,07,23,021
(c) Short Term Provisions	15	1,02,000	92,625
	TOTAL Rs.	14,69,70,272	15,95,91,819

NOTES ON ACCOUNTS

NOTE '1' TO '15' AND NOTE '24'

FORM INTEGRAL PART OF THE BALANCE-SHEET

FOR AND ON BEHALF OF THE BOARD

Charanjit Singh Bhatia

DIRECTOR

Gursimran Singh

DIRECTOR

AUDITOR'S REPORT

As per our report of even date

For HARJEET PARVESH & Co

CHARTERED ACCOUNTANTS

FRN:017437N

DATE : 02.07.2022

PLACE : MOHALI

CA KONICA MADAN

PARTNER

M.No 547759

UDIN:22547759AMCXMG2835

HEALTHY BIOSCIENCES PRIVATE LIMITED
STATEMENT OF PROFIT AND LOSS
FOR THE YEAR ENDED ON 31ST MARCH, 2022

PARTICULARS	NOTES	31ST MARCH 2022	31ST MARCH 2021
<u>INCOMES :</u>			
Revenue from Operations	16	51,94,091	53,16,958
Other Income	17	33,95,559	27,39,251
	TOTAL Incomes Rs.	85,89,649	80,56,209
<u>EXPENSES :</u>			
Cost of Material Consumed	18	42,00,000	63,73,800
Change in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	19	50,430	-20,69,118
Employee Benefit Expenses	20	8,48,763	6,00,000
Finance Cost	21	17,83,564	25,35,504
Depreciation & Amortization Expense		-	-
Other Expenses			
Operating Expenses	22	44,897	2,326
Administrative Expenses	23	6,07,991	1,54,636
	TOTAL Expenses Rs.	75,35,645	75,97,148
NET PROFIT BEFORE INCOME-TAX & EXCEPTIONAL ITEMS		10,54,004	4,59,061
<u>TAX EXPENSE</u>			
(a) Current Tax			
(b) Deferred Tax	24	-9,64,562	-11,29,051
PROFIT FOR THE PERIOD		89,442	-6,69,990
<u>OTHER COMPREHENSIVE INCOME</u>			
<i>Items that will not be classified to Profit and loss:</i>			
Changes in Fair value of FVOCI Equity Instruments & Loss on sale of shares	2	1,47,75,872	-
OTHER COMPREHENSIVE INCOME FOR THE YEAR		1,47,75,872	-
TOTAL COMPREHENSIVE INCOME FOR THE YEAR		1,48,65,314	-
EARNINGS PER SHARE	24	0.001	0.010

NOTES ON ACCOUNTS

NOTE '16' TO '23' AND NOTE '24'

FORM INTEGRAL PART OF THE ACCOUNT

FOR AND ON BEHALF OF THE BOARD

Charanjit Singh Bhatia
DIRECTOR

Gursimran Singh
DIRECTOR

AUDITOR'S REPORT
As per our report of even date
For HARJEET PARVESH & Co
CHARTERED ACCOUNTANTS
FRN :017437N

DATE : 02.07.2022
PLACE : MOHALI

CA Konica Madan
PARTNER
Mno 547759
UDIN:22547759AMCXMG2835

HEALTHY BIOSCIENCES PRIVATE LIMITED

Cash Flow Statement for the year ended 31st March 2022

Particulars	Year ended 31st March 2022 Amount	Year ended 31st March 2021 Amount
A. Cash Flow from Operating Activities:		
Profit before tax for the year	10,54,003.84	4,59,060.74
Adjustments for :		
Interest Expense	17,83,564.15	25,35,504.15
Operating Profit Before Prior Period Items and Working Capital Changes	28,37,567.99	29,94,564.89
Operating Profit Before Working Capital Changes	28,37,567.99	29,94,564.89
Adjustments for:		
Trade and Other Receivables	(17,60,000.00)	
Inventories	50,430.01	(20,69,118.26)
Loans and Advances	2,95,79,538.04	16,62,369.48
Current assets	(1,94,443.00)	(71,613.00)
Other Current Liabilities	-60,30,975.00	(25,16,158.30)
Trade and Other Payables	6,60,100.00	24,25,752.70
Cash Generated from Operations	2,51,42,218.04	24,25,797.51
Income Tax Paid		
Net Cash from Operating Activities	2,51,42,218.04	24,25,797.51
B. Cash Flow from Investing Activities:		
Purchase of Fixed Assets/ Capital Work-In-Progress	0.00	(1,92,528.00)
Investments	-4,77,079.29	(24,81,183.11)
Security	-7,609.00	(3,326.00)
Sale proceeds of fixed assets		4,58,000.00
Net Cash (used)/Generated in Investing Activities	(4,84,688.29)	(22,19,037.11)
C. Cash Flow from Financing Activities:		
Proceed from Share Capital		
Proceeds/ (Repayment) of Long Term Borrowings	-37,80,656.00	37,80,656.00
Proceeds/ (Repayment) of Short Term Borrowings	-1,92,99,892.07	(18,29,560.00)
Interest Paid	(17,83,564.15)	(25,35,504.15)
Net Cash (Used)/Generated in Financing Activities	(2,48,64,112.22)	(5,84,408.15)
Net Increase in Cash and Cash Equivalents (A)+(B)+(C)	(2,06,582.47)	(3,77,647.75)
Opening Cash and Cash Equivalents	16,85,724.94	20,63,372.69
Closing Cash and Cash Equivalents	14,79,142.47	16,85,724.94

FOR HEALTHY BIOSCIENCES PRIVATE LIMITED

As per our separate report of even date attached
For Harjeet Parvesh & Co.
Chartered Accountants

Charanjit Singh Bhatia
(Director)

Gursimran Singh
(Director)

CA Konica Madan
M.No 547759
UDIN:22547759AMCXMG2835

DATE : 02.07.2022
PLACE : MOHALI

HEALTHY BIOSCIENCES PRIVATE LIMITED
AS AT 31ST MARCH, 2022

NOTE 01 : FIXED ASSETS

BLOCK	PARTICULARS	GROSS BLOCK					Salvage Value	DEPRECIATION				NET BLOCK	
		Balance as at 01-04-2021	Additions during the Year	Sales / Adjustment During the year	Balance as at 31-03-2022	RATES		Upto 01-04-2021	During the Year	Transferred to Retained Earnings	Total as at 31-03-2022	As at 31-03-2022	As at 31-03-2021
BLOCK I	<u>LAND & BUILDING</u>												
	- Land	4,46,38,496.00	0.00	0.00	4,46,38,496.00			0.00	0.00	0.00	0.00	4,46,38,496.00	4,46,38,496.00
	- Building	49,39,024.00	0.00		49,39,024.00	3.17%	2,46,951	7,35,732.22	0.00	0.00	7,35,732.22	42,03,291.78	42,03,291.78
BLOCK II	<u>FURNITURE & FIXTURE</u>												
	- Furniture & Fittings	15,89,000.00	0.00	0.00	15,89,000.00	9.50%	79,450	6,93,046.00	0.00	0.00	6,93,046.00	8,95,954.00	8,95,954.00
BLOCK III	<u>MOTOR VEHICLES</u>												
	- Vehicles	34,81,000.00	0.00	0.00	34,81,000.00	11.88%	1,74,050	14,82,299.17	0.00	0.00	14,82,299.17	19,98,700.83	19,98,700.83
BLOCK IV	<u>PLANT & MACHINERY</u>												
	- Plant & Machinery	4,30,33,000.00	0.00	0.00	4,30,33,000.00	7.06%	21,51,650	69,14,640.66	0.00	0.00	69,14,640.66	3,61,18,359.34	3,61,18,359.34
	- Lab Equipement	4,08,000.00	0.00	0.00	4,08,000.00	9.50%	20,400	82,398.20	0.00	0.00	82,398.20	3,25,601.81	3,25,601.81
	- Tools & Dies	7,01,000.00	0.00	0.00	7,01,000.00	21.11%	35,050	3,86,003.27	0.00	0.00	3,86,003.27	3,14,996.73	3,14,996.73
	- Electric Installation	4,39,000.00	0.00	0.00	4,39,000.00	9.50%	21,950	1,02,967.17	0.00	0.00	1,02,967.17	3,36,032.84	3,36,032.84
BLOCK V	<u>OFFICE EQUIPMENTS</u>												
	- Office Equipment	12,90,000.00	0.00	0.00	12,90,000.00	38.08%	64,500	10,26,185.50	0.00	0.00	10,26,185.50	2,63,814.50	2,63,814.50
BLOCK VI	<u>COMPUTERS</u>												
	- Computer	2,94,000.00	0.00	0.00	2,94,000.00	31.67%	14,700	2,83,969.84	0.00	0.00	2,83,969.84	10,030.16	10,030.16
	TOTAL (A)	10,08,12,520.00	0.00	0.00	10,08,12,520.00		28,08,701.20	1,17,07,242.02	0.00	0.00	1,17,07,242.02	8,91,05,277.98	8,91,05,277.98
	PREVIOUS YEAR	10,10,77,992.00	1,92,528.00	4,58,000.00	10,08,12,520.00		28,08,701.20	1,17,07,242.02	0.00	0.00	1,17,07,242.02	8,91,05,277.98	8,93,70,749.98

Note : Depreciation is not charged during the year as according to management there is no business carried on by the company except trading and assets have not been put to use.

FOR & ON BEHALF OF THE BOARD

Charanjit Singh Bhatia
DIRECTOR

Gursimran Singh
DIRECTOR

HEALTHY BIOSCIENCES PRIVATE LIMITED
AS AT 31ST MARCH, 2022
NOTE '1' TO '24' ANNEXED TO AND FORMING PART OF THE
BALANCE SHEET AS ON 31ST MARCH, 2022 AND STATEMENT OF PROFIT & LOSS
FOR THE YEAR ENDED ON THAT DAY

PARTICULARS	31ST MARCH 2022	31ST MARCH 2021
<u>NOTE : 2 - NON CURRENT INVESTMENTS</u>		
Quoted Shares		
<u>Ajooni Biotech Limited</u>	3,04,45,712	1,35,71,640
13,82,296 Shares including 9,29,908 issued as bonus share		
The originally purchased share are valued at Rs 30 Each		
At 31.03.2022 M.V IS 67.3/- per share		
<u>Karda Construction Co</u>	-	24,81,183
The company held 22,000/- shares as on 1.04.2021, further got 8000/- shares in purchase and 30,000/- shares as stock split and 240000/- shares as bonus .		
The company sold 1,00,000/- shares during year and as closing		
The company holds 2,00,000/- bonus shares as at 31.03.2022		
<u>Radhika Jeweltech</u>	8,60,063	-
4950 shares @165.44		
mv on 31.03.2022 =173.75		
TOTAL Rs.	3,13,05,775	1,60,52,823
<u>NOTE :3-OTHER NON CURRENT ASSETS</u>		
Securities	2,41,024	2,33,415
TOTAL Rs.	2,41,024	2,33,415
<u>NOTE : 4-INVENTORIES</u>		
(As per inventories taken, valued and certified by the management)		
Finished Goods / Traded Goods	62,83,468	63,33,898
TOTAL Rs.	62,83,468	63,33,898
<u>NOTE : 5- CASH & CASH EQUIVALENTS</u>		
Bank Balances	73,755	63,114
Cash in Hand	14,05,387	16,22,611
TOTAL Rs.	14,79,142	16,85,725

FOR & ON BEHALF OF THE BOARD

Charanjit Singh Bhatia
DIRECTOR

Gursimran Singh
DIRECTOR

HEALTHY BIOSCIENCES PRIVATE LIMITED
AS AT 31ST MARCH, 2022

PARTICULARS	31ST MARCH 2022	31ST MARCH 2021
-------------	-----------------	-----------------

NOTE : 6- SHORT TERM LOANS & ADVANCES

Tax Collected at Source 19-20	72,000	72,000
Tax Collected at Source 20-21	1,29,562	1,29,562
Tax Collected at Source 21-22	1,44,994	-
Prepaid Expenses	-	6,810
Other Advances	1,48,21,531	4,45,39,253
TOTAL Rs.	1,51,68,087	4,47,47,625

NOTE :7 - TRADE RECEIVABLES

Sundry Debtors	17,60,000	-
TOTAL Rs.	17,60,000	-

Particulars	Outstanding for following periods from due date of payment/Transaction				
	Less than 6 months	6 months - 1 year	1-2 years	2-3 year	TOTAL
(i) Undisputed Trade receivables - considered good	17,60,000.00				17,60,000
(ii) Undisputed Trade Receivables - which have significant increase in credit risk					
(iii) Undisputed Trade Receivables - credit impaired					
(iv) Disputed Trade Receivables- considered good					
(v) Disputed Trade Receivables - which have significant increase in credit risk					
(vi) Disputed Trade Receivables - credit impaired					

NOTE :08- OTHER CURRENT ASSETS

Recoverables from Govt. Authorities (Excise & Vat)	13,61,441	13,61,441
MAT Credit	2,36,015	71,613
Rent recoverable	30,041.00	
<i>-Jay Cee Strips & Fastners Pvt. Ltd.</i>		
TOTAL Rs.	16,27,497.49	14,33,054.49

FOR & ON BEHALF OF THE BOARD

Charanjit Singh Bhatia
DIRECTOR

Gursimran Singh
DIRECTOR

HEALTHY BIOSCIENCES PRIVATE LIMITED
AS AT 31ST MARCH, 2022

PARTICULARS	31ST MARCH 2022	31ST MARCH 2021
-------------	-----------------	-----------------

NOTE : 9- SHARE CAPITAL

AUTHORISED

100,00,000 (100,00,000) Equity Shares of Rs. 10/ each	10,00,00,000.00	10,00,00,000.00
-------------------------------------------------------	-----------------	-----------------

ISSUED, SUBSCRIBED AND PAID UP

1,00,00,000 (1,00,00,000) Equity Shares Of Rs. 10/- Each Fully Paid Up	10,00,00,000.00	10,00,00,000.00
-------------------------------------------------------------------------	-----------------	-----------------

TOTAL Rs.

	10,00,00,000.00	10,00,00,000.00
--	-----------------	-----------------

(c)Reconciliation of the Number of Shares Outstanding at the beginning and at the end of the reporting period

	As at 31st March,2022		As at 31st March,2021	
	No of Shares	Amount	No of Shares	Amount
Equity Shares at the beginning of the year	1,00,00,000.00	10,00,00,000.00	1,00,00,000	10,00,00,000
Add: Equity Shares allotted during the year		-		
Equity Shares at the end of the year	1,00,00,000.00	10,00,00,000.00	1,00,00,000	10,00,00,000

Shareholders holding more than 5 % shares	No. of Equity shares	% of Holding
Punjab Biotechnology Park Limited	1938000	19.38
Paramjit Kaur	1080000	10.80
Ishneet Kaur	1560000	15.60
Sehejbir Singh Bhatia	1922000	19.22
Jasjot Singh	1900000	19.00
Gursimran Singh	1520000	15.20

Shareholders holding by Promoters at the end of the year	No. of Equity shares	% of Holding	% change during year
Punjab Biotechnology Park Limited	1938000	19.38	2.38
Paramjit Kaur	1080000	10.80	
Ishneet Kaur	1560000	15.60	
Sehejbir Singh Bhatia	1922000	19.22	
Jasjot Singh	1900000	19.00	1.00
Gursimran Singh	1520000	15.20	15.20
Upneet Kaur	80000	0.80	0.80
Prism Medico and Pharmacy Limited	0	0	-19.38

FOR & ON BEHALF OF THE BOARD

Charanjit Singh Bhatia
DIRECTOR

Gursimran Singh
DIRECTOR

HEALTHY BIOSCIENCES PRIVATE LIMITED
AS AT 31ST MARCH, 2022

PARTICULARS	31ST MARCH 2022	31ST MARCH 2021
--------------------	------------------------	------------------------

<u>NOTE : 10- OTHER EQUITY</u>	TOTAL Rs.	<div style="border-top: 1px solid black; border-bottom: 3px double black;">95,29,509</div>
---------------------------------------	-----------	--------------------------------------------------------------------------------------------

-53,35,805

PARTICULARS	general reserve & retained earnings (in Rs)	Items of OCI(In Rs)	Total Other Equity
Balance on 1.04.2020	(46,65,814)		(46,65,814)
Pofit for the year	(6,69,990)		(6,69,990)
Items of Other Comprehensive Income			
Balance on 31.03.2021	(53,35,805)	-	(53,35,805)
Balance on 1.04.2021	(53,35,805)		(53,35,805)
Pofit for the year	89,442		89,442
Items of Other Comprehensive Income		1,47,75,872	1,47,75,872
Balance on 31.03.22	(52,46,363.02)	1,47,75,872.10	95,29,509

NOTE : 11 - LONG TERM BORROWINGS

RBL Term Loan	0.00	37,80,656.00
---------------	------	--------------

(EMERGENCY Credit line Gurantee scheme Term loan

ROI =9.25%)

TOTAL Rs.	<div style="border-top: 1px solid black; border-bottom: 3px double black;">0.00</div>	<div style="border-top: 1px solid black; border-bottom: 3px double black;">37,80,656.00</div>
-----------	---------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------

NOTE : 12- SHORT TERM BORROWINGS

RBL Bank CC Limit	-	1,98,38,695.07
-------------------	---	----------------

RBL Term Loan Current Maturity	-	9,39,114.00
--------------------------------	---	-------------

Unsecured Borrowings	26,76,279.00	11,98,362.00
----------------------	--------------	--------------

TOTAL Rs.	<div style="border-top: 1px solid black; border-bottom: 3px double black;">26,76,279.00</div>	<div style="border-top: 1px solid black; border-bottom: 3px double black;">2,19,76,171.07</div>
-----------	-----------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------

FOR & ON BEHALF OF THE BOARD

Charanjit Singh Bhatia
DIRECTOR

Gursimran Singh
DIRECTOR

HEALTHY BIOSCIENCES PRIVATE LIMITED**AS AT 31ST MARCH, 2022****PARTICULARS** **31ST MARCH 2022** **31ST MARCH 2021****NOTE : 13 - TRADE PAYABLES**

Sundry Creditors **2,73,02,523** **2,66,42,423**

TOTAL Rs. **2,73,02,523** **2,66,42,423**

Sno	Particulars	Outstandng for following periods from due date of payment/Transaction				TOTAL
		0-1 years	1-2 years	2-3 Years	More than 3 years	
1	MSME					
2	Others		55,09,600.00	21792922.8	-	2,73,02,522.80
3	Disputed					
	Disputed-MSME					
	Disputed-Others					

NOTE :14 - OTHER CURRENT LIABILITIES

Other Payable's

Statutory Remittance **1,34,625** **51,375**

Advances -Others **37,28,046** **37,35,546**

Advances -Customers **-** **63,86,100**

Security-Rent **5,50,000** **5,50,000**

Cheques Pending Encashment **2,70,000** **-**

TOTAL Rs. **46,82,671** **1,07,23,021**

NOTE : 15 - SHORT TERM PROVISIONS

Provision for Expenses **1,02,000** **92,625**

TOTAL Rs. **1,02,000** **92,625**

FOR & ON BEHALF OF THE BOARDCharanjit Singh
DIRECTORGursimran Singh
DIRECTOR

HEALTHY BIOSCIENCES PRIVATE LIMITED**AS AT 31ST MARCH, 2022**

PARTICULARS	31ST MARCH 2022	31ST MARCH 2021
-------------	-----------------	-----------------

NOTE : 16- REVENUE FROM OPERATIONS**Sale of Products:**

(i) Domestic Sales (Tax Free)	51,94,091	53,16,958
TOTAL Rs.	51,94,091	53,16,958

NOTE : 17 - OTHER INCOME

(i) Rent Received	33,85,500	27,30,000
(ii) Dividend Received	1,350	-
(iii) Interest	8,455	9,251
(iv) Round off	254	-
TOTAL Rs.	33,95,559	27,39,251

NOTE :18 COST OF MATERIAL CONSUMED

Purchases of Raw material& Packing Material	42,00,000	63,73,800
TOTAL Rs.	42,00,000	63,73,800

NOTE 19 - CHANGE IN INVENTORIES**Finished Goods / Traded Goods**

Opening Stock of Finished Goods	11,25,710	11,25,710
Opening Stock of Traded Goods	20,69,118	
Stock Transfer From Raw Material		31,39,070
LESS:		
Closing stock of Trading Goods	20,18,688	20,69,118
Closing Stock of Finished goods	11,25,710	11,25,710
Stock Transfer From Raw Material		31,39,070
TOTAL Rs.	50,430	-20,69,118

FOR & ON BEHALF OF THE BOARD**Charanjit Singh
DIRECTOR****Gursimran Singh
DIRECTOR**

HEALTHY BIOSCIENCES PRIVATE LIMITED**AS AT 31ST MARCH, 2022**

PARTICULARS	31ST MARCH 2022	31ST MARCH 2021
-------------	-----------------	-----------------

NOTE : 20 - EMPLOYEE BENEFIT EXPENSE

(i) Salary, Wages & Allowances	8,48,763	6,00,000
(including Remuneration to Directors)		
TOTAL Rs.	8,48,763	6,00,000

NOTE : 21. - FINANCE COST

Interest Charges	17,79,980	25,30,874
Bank Charges	3,584	4,630
TOTAL Rs.	17,83,564	25,35,504

NOTE : 22 - OTHER OPERATING EXPENSES

Electricity, Power & Water	44,897	2,326
TOTAL Rs.	44,897	2,326

NOTE : 23 ADMINISTRATIVE EXPENSES

Telephone, Fax & Internet	43,131	42,480
Advertisement & Publicity	16,806	-
Postage & Telegram	100	90
Audit Fee	29,500	53,100
Legal & Professional Charges	68,100	26,158
Insurance Charges	65,364	4,090
Rate,Fees & Taxes	3,35,801	21,177
Travelling & Conveyance	110	-
Repair & Maintenance	43,766	-
Miscellaneous Expenses	5,313	7,541
TOTAL Rs.	6,07,991	1,54,636

FOR & ON BEHALF OF THE BOARDCharanjit Singh Bhatia
DIRECTORGursimran Singh
DIRECTOR

HEALTHY BIOSCIENCES PRIVATE LIMITED
NOTE :24- NOTES ON ACCOUNTS & ACCOUNTING POLICIES

Forming part of Balance Sheet and Statement of Profit and Loss
For the Year ended 31st March, 2022

Note 24

A. SIGNIFICANT ACCOUNTING POLICIES :-

The following disclosure of accounting policies is made in pursuance of the recommendation of the Accounting standards Boards of the Institute of Chartered Accountants of India on 'Disclosure of Accounting Policies'.

a) System of Accounting :

The company has adopted Indian Accounting Standards (IndAS) as notified by the Ministry of Corporate Affairs with effect from 01st April 2017 , with a transition date of 01st April 2016. The adoption of IndAs has been carried out in accordance with Ind AS 101, First Time Adoption of Indian Accounting Standards. Ind AS 101 requires that all Ind AS Standards and interpretations that are issued and effective for the First Ind AS Financial Statements for the year ended 31st March 2022, be applied retrospectively and consistently for all financial years presented .

b) Fixed Assets and Depreciation.:

Depreciation is provided on Written Down Value method assuming residual value as 5% over the useful lives of assets estimated by the Management. at the rates specified in Part C of Schedule II of the Companies Act 2013 on Pro rata basis and the Assets having the Value up to Rs 5000.00 have been depreciated at the rate of 100%, Except this year Depreciation amounting Rs 27,12,565.23 is not charged during the year as there is no business carried on by the company except for trading activities and assets have not been put to use. This amount has been calculated on retrospective basis .

c) Inflation :

Assets & Liabilities are recorded at historical cost to the company. These costs are not adjusted to reflect the changing value in the purchasing power of money.

d) Basis of Accounting.

The Accounts of the Company are prepared under the historical cost convention and in accordance with the requirements of the Companies Act, 2013 and accepted accounting standards. The accounts are prepared on accrual basis.

e) Valuation of Inventory

FIFO method of Stock valuation has been adopted by the company. Stock of raw material, stores & spares are valued at cost whereas stock of finished goods is valued at cost or net realisable value whichever is lower.

f) Events Occuring After the Valuation Date

Events occuring after the date of Balance Sheet, are considered up to date of finalisation of accounts, wherever material.

g) Use Of Estimates

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumption that affect the reported balances of assets and liabilities and discloser relating to contingent liabilities as at the date of the financial statements and reported amounts of income and expenses during the period. Examples of such estimates include computation of percentage of completion which requires the company to estimates the efforts or cost expended to date as a proportion to date as a proportion of the total efforts or costs to be expended, provisions for doubtful debts, future obligation under employee retirement benefit plans, income taxes, post-sales customer support and the useful lives of fixed tangible assets and intangible assets.

Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in estimates are made as the Management becomes aware of changes in circumstances surrounding the estimates. Changes in estimates are reflected in the financial statements in the period in which changes are made and, if material, their effects are disclosed in the notes to the financial statements.

h) Recognition Of Income & Expenditure

i) Revenue is recognised to the extent that it is probable that the economic benefits will flow to the company, the significant risks and rewards of ownership have been transferred to the buyer and the revenue can be reliably measured in compliance with IND AS-18

ii) Sales are recognised as & when the goods are supplied and net of GST. However rebate & discount is being seperately shown as other income.

iii) Expenses are accounted for on accrual basis and provision is made for all known losses and expenses.

i) Employee's Benefits

The retirement benefits of the employees include Gratuity, Provident Fund & Contribution to the PF is provided on Accrual basis.No Provision has been made for Leave Encashment

J) Income Tax

Income tax is recognized in the Statement of income except to the extent that it relates to items recognized directly within equity or in other comprehensive income. Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantially-enacted at the reporting date, and any adjustment to tax payable in respect of previous years.

Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes.

Deferred tax assets are recognised for unused tax losses, unused tax credits and deductible temporary differences to the extent that it is probable that future taxable profits will be available against which they can be used. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realised

H) Investments

As per IND AS , Investments in financial instruments be recognised at fair value and any change in the value should be recognised through FVTPL/FVOCI method.The investments are at recognised at fair value through FVOCI method.

B. NOTES ON ACCOUNTS :-

- Previous year figure have been re-grouped / re-arranged / re-caste wherever considered necessary, to suit the current year's layout as per the performa of Revised Schedule III as per IND AS requirements
- In the opinion of the Board, the current assets, loans & advances have a value on realisation in the ordinary course of business atleast equal to the amount at which they are stated in the balance sheet and that the provision for known liabilities are adequate and not in excess of amount reasonably necessary.

3. EPS CALCULATION

Particulars	2021-22	2020-21
Profit available for Equity Shareholders	89,441.67	(6,69,990.26)
For Basic Earning:	89,441.67	(6,69,990.26)
No. of Weighted Average Equity Shares		
For Diluted Earning:	1,00,00,000.00	1,00,00,000.00
Effect of Diluted Equity Shares equivalent to Pending for Allotment		
No. of Weighted Average of Diluted Equity Shares	1,00,00,000.00	1,00,00,000.00
Nominal Value of Equity Shares		
Earning Per Share (Rs.):	10	10
Basic	0.00	(0.01)
Diluted	0.00	(0.01)

- With reference to Employee Benefits, no provision has been made regarding Gratuity, Leave encashment & other retirement benefits & in absence of actuarial valuation there impact on financial statements are unascertainable.
- Related Party disclosures are required under the Accounting standard (IAS-24) on "Related Party Disclosures" issued are given below:-

a.) Relationship

- Holding Company None
- Key Management Personnel (Managing / Whole Time Director)

(i) Charanjit Singh**(ii) Mr. Gursimran Singh****c) Related Party Transaction**

c. Related Party Transaction	2021-22	2020-21
Description		
1.Transaction during the year		
Prism Medico And Pharmacy Ltd		
Repayment made against purchases	35,99,000.00	60,000.00
With Ajooni Biotech Pvt Ltd		
Sale made during the year	-	34,00,610.00
Purchases within the year	42,00,000.00	
2. Rent received	2,83,200.00	2,83,200.00

- The Balance in the parties account whether debit or credit are subject to confirmation, reconciliation and adjustment.
- Estimated amount of contracts remaining to be executed on capital account and not provided for (Net of Advances)

8. Contingent Liabilities not provided for :	2021-22	2020-21
a. Bank Guarantees	Nil	Nil
b. Contingent Liabilities in respect of unassessed cases of Income Tax and Sales Tax.	Unascertained	Unascertained
c. Uncalled Liabilities as Shares partly paid	Nil	Nil
d. Claims not Acknowledged as debts	Nil	Nil
e. Letter of Credit(s)	Nil	Nil

9. CIF value of imports	31st March, 2022	31st March, 2021
10. Remittance in foreign Currency	Nil	Nil
11. Expenditure in Foreign Currency	Nil	Nil
12. Earning in Foreign Currency	Nil	Nil

- In the opinion of Board of Directors, the Current Assets, Loan & advances shown in the Balance sheet have a value on realisation in the ordinary course of business at least equal to the amount at which they are stated.

14. Auditors' Remuneration

31.03.2022

31.03.2021

As Statutory Audit Fee

29,500.00

29,500.00

Total Rs.

29,500.00

29,500.00

15. Deferred Taxation

In conformity with IND AS 12 "Deferred tax Liability/ Asset is as follows :-

PARTICULARS	Current Year	Previous Year
Difference on Account of Depreciation	-37,09,854	-43,42,506
Total Timing Difference	-37,09,854	-43,42,506
Tax Rate	26	26
Deferred Tax Liability created on Timing Difference	9,64,562	11,29,051
Opening DTA/DTL	17,12,728	5,83,677
Total Deferred Tax Liability	26,77,290	17,12,728

We have not created DTA on loss because we don't see any Virtual Certainty to recover such losses.

Deferred Tax Due to Depreciation :Timing Difference on Depreciation

CURRENT YEAR

PREVIOUS YEAR

Depreciation as per Books of Accounts

-

-

Depreciation as per Income Tax Act

37,09,854

43,42,506

Timing Difference (Less Allowance By Income Tax)

(37,09,854)

(43,42,506)

16. KEY RATIOS AS ON 31.03.2022

PARTICULARS	RATIO
1) CURRENT RATIO	0.82
2) DEBT -EQUITY RATIO	0.02
3) DEBT SERVICE COVERAGE RATIO	1.06
4) RETURN ON EQUITY RATIO	0.001
5) INVENTORY TURNOVER RATIO	0.82
6) TRADE RECEIVABLES TURNOVER RATIO	5.90
7) TRADE PAYABLES TURNOVER RATIO	0.16
8) NET CAPITAL TURNOVER RATIO	0.94
9) NET PROFIT RATIO	0.017
10) RETURN ON CAPITAL EMPLOYED RATIO	0.028
11) RETURN ON INVESTMENT	0.028

17. Details of Shareholders

Details of Shareholders have been attached as per Annexure "B".

18. Rounding off has been done to nearest 10.

19. Others

Depreciation is not charged during the year as according to management there is no business carried on by the company except for trading activities and assets have not been put to use. Hence the expenses are reduced by Rs 27,12,565.23 i.e amount of depreciation charged during year, hence resulting in increased profit.

FOR AND ON BEHALF OF THE BOARDAUDITOR'S REPORT

As per our report of even date

FOR HARJEET PARVESH & CO
CHARTERED ACCOUNTANTS
FRN :017437N

Charanjit Singh Bhatia
DIRECTOR

Gursimran Singh
DIRECTOR

DATE: 02.07.2022
PLACE : Mohali

CA KONICA MADAN
M No. 547759